Development and characterization of a transdermal patch and an emulgel containing kanamycin intended to be used in the treatment of mycetoma caused by Actinomadura madurae

Drug Development and Industrial Pharmacy
Miriam López-CervantesAdriana Ganem-Quintanar

Abstract

Mycetoma is a chronic, degenerative, and incapacitating infection of the skin and subcutaneous tissue. This study focuses on developing a kanamycin-based auxiliary system intended to be used in the treatment of mycetoma caused by Actinomadura madurae. Transdermal patches (with two different formulations: one with free kanamycin [K] and the other one with kanamycin adsorbed in silica [K-SG]) and an emulgel were developed. Both patches were prepared by the casting-evaporation technique. To characterize them, differential scanning calorimetry, bioadhesion, post-moisture detachment, strength and rupture distance, gas exchange, water uptake, and dissolution studies were carried out. The emulgel (containing 0.57% of kanamycin) was prepared from an oil-in-water emulsion, which was then incorporated to a gel. the patches with the best characteristics contained 22.9% of silica and 14.6% of kanamycin. Dissolution studies indicated that 8.8% of kanamycin released from K and 3.2% from K-SG at 24h. The emulgel containing 0.57% of kanamycin showed good technological characteristics for its application to the skin (viscosity, 44.9 +/- 1.4 poises; pH, 6.9 +/- 0.4; and penetrability, 52.7 +/- 5.1). The optimal patches were those containing 15.9...Continue Reading

References

Mar 1, 1990·Antimicrobial Agents and Chemotherapy·J BrajtburgG Medoff
Feb 1, 1971·The Journal of Infectious Diseases·A Molavi, L Weinstein
Nov 1, 1981·Reviews of Infectious Diseases·R R Tight, M S Bartlett
Jan 1, 1993·Folia Microbiologica·C PerezG R Castro
Mar 21, 1998·Journal of Clinical Microbiology·A O Ahmed, E S Abugroun
Aug 12, 2000·International Journal of Dermatology·D RigopoulosA Katsambas
Jan 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edina H MoylettRichard J Wallace
Mar 12, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Cristina PadulaPatrizia Santi
May 29, 2003·FEMS Immunology and Medical Microbiology·Angel Licón-TrilloMario César Salinas-Carmona
Aug 2, 2003·Journal of the American Academy of Dermatology·Kathrin Elisabeth DouwesThomas Vogt
Nov 25, 2005·Current Drug Delivery·Mario Grassi, Gabriele Grassi
Nov 29, 2005·Journal of the American Academy of Dermatology·Omar LupiMichael R McGinnis
Aug 7, 2007·Indian Journal of Dermatology, Venereology and Leprology·M RamamC Rajendran
Jan 10, 2008·Journal of Pharmaceutical and Biomedical Analysis·Z Urbán-MorlánD Quintanar-Guerrero
Feb 21, 2008·Antimicrobial Agents and Chemotherapy·Alejandra Daw-GarzaLucio Vera-Cabrera

❮ Previous
Next ❯

Citations

Dec 17, 2011·Expert Opinion on Drug Delivery·Francesco CilurzoPaola Minghetti
Jul 9, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society· AjazuddinDulal Krishna Tripathi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Mária SzucsIstván Eros
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
Rachit KhullarSeema Saini
© 2022 Meta ULC. All rights reserved